BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2015-01-12

Last Posted Date: 2022-01-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 213

Registration Number: NCT02335606

Locations: 🇨🇳
Local Institution, Taipei, Taiwan

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BMS-963272
Drug: Placebo

First Posted Date: 2014-12-30

Last Posted Date: 2015-07-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 88

Registration Number: NCT02327273

Locations: 🇺🇸
Ppd Development, Lp, Austin, Texas, United States

A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir

Phase 1

Completed

Conditions: Hepatitis C Infection

Interventions: Drug: Daclatasvir
Drug: Asunaprevir

First Posted Date: 2014-12-23

Last Posted Date: 2015-02-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 88

Registration Number: NCT02323594

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2014-12-19

Last Posted Date: 2021-10-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 119

Registration Number: NCT02320058

Locations: 🇺🇸
UCLA Medical Hematology and Oncology, Los Angeles, California, United States
🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States

and more 33 locations

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Sofosbuvir
Drug: Ribavirin

First Posted Date: 2014-12-18

Last Posted Date: 2017-01-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 53

Registration Number: NCT02319031

Locations: 🇫🇷
Local Institution, Vandoeuvre Les Nancy, France

Taste Properties of Atazanavir and Cobicistat

Phase 1

Completed

Conditions: HIV in Adults

Interventions: Drug: Atazanavir
Drug: Cobicistat
Drug: Active Pharmaceutical Ingredient

First Posted Date: 2014-12-04

Last Posted Date: 2022-01-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6

Registration Number: NCT02307656

Locations: 🇺🇸
Senopsys Llc, Woburn, Massachusetts, United States

An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Leukemia

Interventions: Drug: BMS-936564
Drug: Cytarabine

First Posted Date: 2014-12-02

Last Posted Date: 2021-09-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT02305563

Locations: 🇺🇸
Ucla Center Health Sci, Los Angeles, California, United States
🇧🇷
Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, Sao Paulo, Brazil
🇧🇷
Liga Paranaense De Combate Ao Cancer Erasto Gaertner, Curitiba, Parana, Brazil

and more 13 locations

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Phase 2

Completed

Conditions: Multiple Indications Cancer

Interventions: Drug: Dasatinib

First Posted Date: 2014-11-21

Last Posted Date: 2023-05-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 17

Registration Number: NCT02297139

Locations: 🇵🇱
Local Institution, Lodz, Poland
🇵🇱
Local Institution - 0006, Kraków, Małopolskie, Poland
🇵🇱
Local Institution - 0002, Wroclaw, Poland

and more 1 locations

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BMS-986147
Drug: Placebo matching BMS-986147

First Posted Date: 2014-11-18

Last Posted Date: 2015-05-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT02293629

Locations: 🇺🇸
Wcct Global, Llc, Cypress, California, United States

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

Phase 1

Completed

Conditions: Solid Tumors That Overexpress HER2 (HER2 Positive)

Interventions: Drug: FS102

First Posted Date: 2014-11-07

Last Posted Date: 2017-09-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT02286219

Locations: 🇺🇸
The West Clinic, Memphis, Tennessee, United States
🇺🇸
Anthony El-Khoueiry, Md, Los Angeles, California, United States
🇺🇸
Southwest Texas Addiction Research And Tech (Start) Center, San Antonio, Texas, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy